Cited by 11Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCancer Cells and Metastasis

Mesenchymal‐like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial‐like counterparts

Open access
Sinha, Arkadeep, Cherba, David, Bartlam, Heather, Lenkiewicz, Elizabeth, Evers, Lisa, Barrett, Michael T., Haab, Brian B.·2014·Molecular Oncology

Abstract

The aggressiveness of pancreatic cancer is associated with the acquisition of mesenchymal characteristics by a subset of pancreatic cancer cells. The factors driving the development of this subset are not well understood. In this study, we tested the hypothesis that acquisition of a mesenchymal phenotype occurs selectively in tumor cells that harbor specific enabling genetic alterations. We obtained whole‐genome comparative genomic hybridization (CGH) measurements on pancreatic cancer cell lines that have either an epithelial‐like (17 cell lines) or a mesenchymal‐like (9 cell lines) phenotype in vitro. The total amounts of amplifications and deletions were equivalent between the epithelial and mesenchymal groups, but 20 genes showed a major difference between the groups in prevalence of alterations. All 20 alterations (18 deletions and 2 amplifications) were more prevalent in the mesenchymal group, confirming the advanced nature of this cellular subtype. CDKN2A was altered in more than 50% of both groups, but co‐deletions in neighboring genes, and concomitant loss of gene expression, were more prevalent in the mesenchymal group, suggesting that the size of the loss around CDKN2A affects cell phenotype. Whole‐genome CGH on 11 primary cancer tissues revealed that the 20 genes were altered at a higher prevalence (up to 55% of the cases for certain genes) than randomly selected sets of 20 genes, with the same direction of alteration as in the cell lines. These findings support the concept that specific genetic alterations enable phenotype plasticity and provide promising candidate genes for further research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.04.007

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 79 · Cited by 11

Research works printed but not linked: 2

  1. Jesse S Koenig A Ellenrieder V Menke A Lef-1 isoforms regulate different target genes and reduce cellular adhesion. Int J Cancer 2010 126 1109 1120 19653274
  2. Kwei KA Shain AH Bair R Montgomery K Karikari CA van de Rijn M Hidalgo M Maitra A Bashyam MD Pollack JR SMURF1 amplification promotes invasiveness in pancreatic cancer. PLoS One 2011 6 e23924 21887346 PMC3161761

Authors
Sinha, A., Cherba, D., Bartlam, H., Lenkiewicz, E., Evers, L., Barrett, M. T., & Haab, B. B.
Affiliations
  • Van Andel Institute (US)
  • Translational Genomics Research Institute (US)
Corresponding author
Haab, Brian B.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-05-02
Volume
8
Issue
7
Pages
1253-1265
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2131920891
Cited by
11
References
79
Citations by year
2026: 1 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2014: 1
FWCI
0.16
Type
journal article
Language
en
Open access
Locations
  • Molecular Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
NCI (R03CA139225, 5P01CA109552-04, 1R21CA137687)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
pancreatic cancer, mesenchymal phenotype, epithelial-mesenchymal transition, tumor heterogeneity, genetic alterations, CDKN2A, gene deletion, gene amplification, phenotypic plasticity, pancreatic cancer cell lines, candidate genes
MeSH terms
Humans, Pancreas, Pancreatic Neoplasms, Gene Expression Regulation, Neoplastic, Gene Dosage, Genomics, Cell Line, Tumor, Comparative Genomic Hybridization, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review